Abstract
To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice. An observational, retrospective study was performed. Patients aged ≥30 years treated with metformin who initiated a second oral antidiabetic treatment in 2009 to 2010 were included. Two groups of patients were analysed: metformin+DPP-4 inhibitors and other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated hemoglobin< 7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for 2 years. We included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin+DPP-4 inhibitors and 260 patients received metformin+other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%), and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (P<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), P=0.001. Despite the limitations of the study, patient...Continue Reading
References
May 1, 1991·Medical Care·J P WeinerL M Mumford
Jan 1, 1987·Journal of Chronic Diseases·M E CharlsonC R MacKenzie
Jan 1, 1993·Scandinavian Journal of Primary Health Care. Supplement·F B KristensenL C Lassen
Apr 28, 2000·BMJ : British Medical Journal·S G Thompson, J A Barber
Feb 28, 2004·Diabetes Care·Johan FageruddUNKNOWN FinnDiane Study Group
May 19, 2005·Treatments in Endocrinology·Pierre-Jean Guillausseau
Nov 7, 2007·International Journal of Clinical Practice·J A CramerZ M Khan
Dec 2, 2009·Journal of Medical Economics·L BreitscheidelO Schöffski
Feb 15, 2011·International Journal of Clinical Practice·C J Bailey, M Kodack
Mar 15, 2011·Clinical Therapeutics·Carl AscheChris Conner
Aug 5, 2011·Drugs·Roberta Baetta, Alberto Corsini
Dec 27, 2011·Diabetes & Metabolism·A J Scheen
Feb 2, 2012·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·György JermendyBéla Merkely
Jun 14, 2012·Diabetes, Obesity & Metabolism·W KothnyV Lukashevich
Jul 4, 2012·Journal of the American Medical Directors Association·Alan SinclairKate Lorig
Aug 24, 2012·Postgraduate Medicine·Jennifer B Green
Oct 23, 2012·Endocrine·Gianfranco Tramonti, Yashpal S Kanwar
Nov 22, 2012·Current Diabetes Reviews·Peter Noel Van Buren, Robert Toto
Dec 18, 2012·Expert Opinion on Drug Safety·Stephanie Aleskow SteinStephen N Davis
Jan 15, 2013·Vascular Pharmacology·Mandeep Kumar Arora, Umesh Kumar Singh
Feb 5, 2013·Vascular Health and Risk Management·Valentina LukashevichWolfgang Kothny
Apr 17, 2013·The Journal of Clinical Endocrinology and Metabolism·Elizabeth R SeaquistUNKNOWN Endocrine Society
Jun 12, 2013·Postgraduate Medicine·André J Scheen
Jul 23, 2013·Revista clínica española·A Sicras MainarJ Ibáñez Nolla
Citations
Jul 7, 2015·BioMed Research International·Wellington Santana da Silva JúniorLuiz Guilherme Kraemer-Aguiar
Apr 30, 2015·Diabetes & Metabolism Journal·Hannah Seok
Apr 30, 2015·Diabetes & Metabolism Journal·Antoni Sicras-Mainar, Ruth Navarro-Artieda